NxStage Medical, Inc. (NASDAQ:NXTM) – Analysts at Leerink Swann dropped their FY2017 earnings estimates for NxStage Medical in a report issued on Wednesday. Leerink Swann analyst D. Antalffy now expects that the medical device company will post earnings of ($0.05) per share for the year, down from their previous forecast of ($0.02). Leerink Swann has a “Market Perform” rating and a $30.00 price target on the stock.

NxStage Medical (NASDAQ:NXTM) last posted its earnings results on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). The company had revenue of $92.20 million during the quarter, compared to the consensus estimate of $96.47 million. NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.03) earnings per share.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2017/09/09/nxstage-medical-inc-expected-to-post-fy2017-earnings-of-0-05-per-share-nxtm.html.

Other research analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a report on Thursday, August 10th. Canaccord Genuity cut shares of NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 target price for the company. in a report on Monday, August 7th. BidaskClub cut shares of NxStage Medical from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Craig Hallum cut shares of NxStage Medical from a “buy” rating to a “hold” rating in a report on Monday, August 7th. Finally, BTIG Research cut shares of NxStage Medical from a “buy” rating to a “neutral” rating in a report on Friday, August 11th. One investment analyst has rated the stock with a sell rating and nine have assigned a hold rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $30.25.

Shares of NxStage Medical (NASDAQ NXTM) opened at 27.88 on Friday. The company’s market capitalization is $1.84 billion. The stock’s 50 day moving average is $27.02 and its 200 day moving average is $25.95. NxStage Medical has a 52-week low of $20.45 and a 52-week high of $30.80.

In other news, President Joseph E. Turk, Jr. sold 1,000 shares of NxStage Medical stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $25.19, for a total value of $25,190.00. Following the completion of the sale, the president now directly owns 75,903 shares in the company, valued at $1,911,996.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Matthew W. Towse sold 4,300 shares of NxStage Medical stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $29.22, for a total transaction of $125,646.00. Following the completion of the sale, the senior vice president now owns 28,721 shares of the company’s stock, valued at $839,227.62. The disclosure for this sale can be found here. Insiders sold 54,900 shares of company stock valued at $1,491,266 over the last quarter. Company insiders own 4.70% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new stake in NxStage Medical during the first quarter valued at approximately $140,000. Ameritas Investment Partners Inc. bought a new stake in NxStage Medical during the first quarter valued at approximately $148,000. Quantitative Systematic Strategies LLC bought a new stake in NxStage Medical during the second quarter valued at approximately $203,000. Amalgamated Bank grew its position in NxStage Medical by 7.1% during the second quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock valued at $210,000 after buying an additional 553 shares during the period. Finally, Menta Capital LLC bought a new stake in NxStage Medical during the first quarter valued at approximately $212,000. Institutional investors own 93.20% of the company’s stock.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Earnings History and Estimates for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.